Vicore Pharma's Phase 2b Buloxibutid Trial in IPF Passes Futility Analysis
Bitget2026/10/22 16:51- Vicore Pharma announced Oct. 22, 2026, its Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis passed a planned futility analysis.
- An independent monitoring committee recommended continuing the trial without modification, identifying no safety concerns.
- The trial completed enrollment of 378 patients in April 2026; final 52-week topline results remain expected in mid-2027.
- Cash runway extends into the second half of 2028, supporting operations beyond the readout.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
UBS CEO warns: A Democratic sweep could slow down AI capacity building, valuation concerns are "very important"
UBS CEO Ermotti stated that the U.S. midterm elections may slow down AI capacity building and that the valuations are questionable; he also warned of persistent inflation and the risk of contagion in the European bond market.
Crypto prices
More
